Greenwich LifeSciences Past Earnings Performance
Past criteria checks 0/6
Greenwich LifeSciences's earnings have been declining at an average annual rate of -37.7%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-37.7%
Earnings growth rate
67.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -132.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Revenue & Expenses BreakdownBeta
How Greenwich LifeSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -9 | 2 | 8 |
| 30 Sep 23 | 0 | -9 | 2 | 8 |
| 30 Jun 23 | 0 | -9 | 2 | 7 |
| 31 Mar 23 | 0 | -8 | 2 | 7 |
| 31 Dec 22 | 0 | -8 | 2 | 6 |
| 30 Sep 22 | 0 | -7 | 1 | 6 |
| 30 Jun 22 | 0 | -6 | 1 | 5 |
| 31 Mar 22 | 0 | -6 | 1 | 5 |
| 31 Dec 21 | 0 | -5 | 1 | 4 |
| 30 Sep 21 | 0 | -3 | 1 | 2 |
| 30 Jun 21 | 0 | -3 | 1 | 2 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 30 Sep 20 | 0 | -1 | 0 | 1 |
| 30 Jun 20 | 0 | -1 | 0 | 1 |
| 31 Mar 20 | 0 | -4 | 1 | 3 |
| 31 Dec 19 | 0 | -3 | 1 | 3 |
Quality Earnings: GLSI is currently unprofitable.
Growing Profit Margin: GLSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLSI is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.
Accelerating Growth: Unable to compare GLSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: GLSI has a negative Return on Equity (-132.71%), as it is currently unprofitable.